Skip to main content

Table 9 Base case results for patients with cirrhosis

From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

Genotype Treatment Duration (weeks) Cost ($) Effectiveness (QALYs) ICER compared to benchmark ($/QALY) Adjacent ICER ($/QALY)
1 Harvoni 12 108,000 19.9787 dominant  
Telaprevir + Peginterferon + Ribavirin for first 12 weeks, followed by additional 12 or 36 weeks of Peginterferon + Ribavirin 12 + 12 or 36 122,420 17.2075 benchmark dominated
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) 12 130,750 17.8475 13,016 dominated
Viekira Pak + Ribavirin 24 186,820 19.7603 25,227 dominated
Olysio + Sovaldi 24 313,310 20.136 65,184 1,305,213
2 Peginterferon + Ribavirin (Treatment-naïve) 24 81,070 15.874 benchmark  
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. 24 + 12 81,920 18.4461 330 330
24 + 16 82,240 19.3293 339 362
Sofosbuvir + Ribavirin (Treatment-naïve) 12 119,940 18.4217 15,257 dominated
3 Peginterferon + Ribavirin (Treatment-naïve) 24 121,170 12.2543 benchmark  
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. 24 + 16 147,520 17.1869 5,342 5,342
24 + 12 162,490 13.8563 25,793 dominated
Sofosbuvir + Ribavirin (Treatment-naïve) 24 191,280 19.3615 9,865 20,123